XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenue (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2021
Disaggregation of Revenue [Abstract] |
Disaggregation of Revenue [Table Text Block] | The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
| Three Months Ended June 30, |  |
| 2021 |  | 2020 |  |  |  |
Businesses | U.S. |  | Int'l |  | Total |  | U.S. |  | Int'l |  | Total |  |  |  |  |  |  |  |
Endoscopy | $ | 316 |  |  | $ | 235 |  |  | $ | 551 |  |  | $ | 190 |  |  | $ | 158 |  |  | $ | 348 |  |  |  |  |  |  |  |  |
Urology and Pelvic Health | 285 |  |  | 112 |  |  | 397 |  |  | 162 |  |  | 66 |  |  | 228 |  |  |  |  |  |  |  |  |
Cardiac Rhythm Management | 314 |  |  | 210 |  |  | 524 |  |  | 208 |  |  | 143 |  |  | 351 |  |  |  |  |  |  |  |  |
Electrophysiology | 34 |  |  | 62 |  |  | 95 |  |  | 22 |  |  | 30 |  |  | 51 |  |  |  |  |  |  |  |  |
Neuromodulation | 194 |  |  | 53 |  |  | 247 |  |  | 100 |  |  | 23 |  |  | 122 |  |  |  |  |  |  |  |  |
Interventional Cardiology | 398 |  |  | 392 |  |  | 790 |  |  | 189 |  |  | 306 |  |  | 495 |  |  |  |  |  |  |  |  |
Peripheral Interventions | 260 |  |  | 213 |  |  | 473 |  |  | 189 |  |  | 151 |  |  | 340 |  |  |  |  |  |  |  |  |
Specialty Pharmaceuticals | — |  |  | — |  |  | — |  |  | 60 |  |  | 8 |  |  | 68 |  |  |  |  |  |  |  |  |
Net Sales | $ | 1,800 |  |  | $ | 1,277 |  |  | $ | 3,077 |  |  | $ | 1,118 |  |  | $ | 885 |  |  | $ | 2,003 |  |  |  |  |  |  |  |  |
On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales for the first six months of 2021 include Specialty Pharmaceuticals up to the date of the closing of the transaction.
| Six Months Ended June 30,
| 2021 |  | 2020
Businesses | U.S. |  | Int'l |  | Total |  | U.S. |  | Int'l |  | Total
Endoscopy | $ | 596 |  |  | $ | 454 |  |  | $ | 1,050 |  |  | $ | 445 |  |  | $ | 345 |  |  | $ | 790 |
Urology and Pelvic Health | 542 |  |  | 216 |  |  | 758 |  |  | 400 |  |  | 161 |  |  | 560 |
Cardiac Rhythm Management | 590 |  |  | 403 |  |  | 993 |  |  | 463 |  |  | 325 |  |  | 788 |
Electrophysiology | 64 |  |  | 115 |  |  | 179 |  |  | 53 |  |  | 72 |  |  | 126 |
Neuromodulation | 345 |  |  | 99 |  |  | 444 |  |  | 250 |  |  | 63 |  |  | 313 |
Interventional Cardiology | 741 |  |  | 745 |  |  | 1,486 |  |  | 486 |  |  | 642 |  |  | 1,128 |
Peripheral Interventions | 498 |  |  | 407 |  |  | 906 |  |  | 413 |  |  | 319 |  |  | 732 |
Specialty Pharmaceuticals | 10 |  |  | 4 |  |  | 13 |  |  | 97 |  |  | 12 |  |  | 109 |
Net Sales | $ | 3,386 |  |  | $ | 2,443 |  |  | $ | 5,829 |  |  | $ | 2,607 |  |  | $ | 1,939 |  |  | $ | 4,546 |
| Three Months Ended June 30, |  | Six Months Ended June 30,
Geographic Regions | 2021 |  | 2020 |  | 2021 |  | 2020
U.S. | $ | 1,800 |  |  | $ | 1,058 |  |  | $ | 3,376 |  |  | $ | 2,510 |
EMEA (Europe, Middle East and Africa) | 662 |  |  | 416 |  |  | 1,266 |  |  | 968 |
APAC (Asia-Pacific) | 520 |  |  | 410 |  |  | 994 |  |  | 819 |
LACA (Latin America and Canada) | 95 |  |  | 51 |  |  | 180 |  |  | 140 |
Medical Devices | 3,077 |  |  | 1,935 |  |  | 5,816 |  |  | 4,437 |
U.S. | — |  |  | 60 |  |  | 10 |  |  | 97 |
International | — |  |  | 8 |  |  | 4 |  |  | 12 |
Specialty Pharmaceuticals | — |  |  | 68 |  |  | 13 |  |  | 109 |
Net Sales | $ | 3,077 |  |  | $ | 2,003 |  |  | $ | 5,829 |  |  | $ | 4,546 |
Emerging Markets(1) | $ | 359 |  |  | $ | 268 |  |  | $ | 676 |  |  | $ | 542 |
(1) We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2021, modified our list to include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. We have revised prior period amounts to conform to the current year's presentation which had an immaterial impact on previously reported Emerging Markets net sales.

X
- References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration